Posted by Michael Wonder on 22 Sep 2020
NICE publishes draft guidance on new use for Kyprolis
22 September 2020 - The guidance relates to the use of carfilzomib with dexamethasone and lenalidomide for patients with previously treated multiple myeloma.
Carfilzomib with lenalidomide and dexamethasone is not recommended, within its marketing authorisation, for previously treated multiple myeloma in adults.
Clinical trial evidence shows that carfilzomib with lenalidomide and dexamethasone gives longer periods of remission and people live longer than with lenalidomide and dexamethasone. It also suggests that people live longer than 24 months.
However, there is uncertainty about how long the benefit lasts after stopping treatment. This makes the cost-effectiveness estimates uncertain.
